bufalin has been researched along with arginyl-glycyl-aspartic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, Y; Hou, L; Li, Q; Liu, P; Liu, X; Qin, J; Qiu, M; Qiu, Y; Wang, Y; Yin, P | 1 |
| Fan, G; Gao, F; Han, L; He, X; Huang, X; Qiu, Y; Tang, X; Xu, K; Yin, P; Yuan, Y; Yuan, Z; Zhang, Y | 1 |
2 other study(ies) available for bufalin and arginyl-glycyl-aspartic acid
| Article | Year |
|---|---|
Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity.
Topics: Animals; Antineoplastic Agents; Bufanolides; Cell Survival; Colonic Neoplasms; Drug Carriers; Female; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Oligopeptides; Particle Size; Polyesters; Polyethylene Glycols; Polylysine; Spectrophotometry, Ultraviolet; Tissue Distribution; Xenograft Model Antitumor Assays | 2012 |
Bufalin-loaded vitamin E succinate-grafted-chitosan oligosaccharide/RGD conjugated TPGS mixed micelles demonstrated improved antitumor activity against drug-resistant colon cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bufanolides; Chitosan; Colonic Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; HCT116 Cells; Humans; Mice, Nude; Micelles; Oligopeptides; Oligosaccharides; Rhodamine 123; Tumor Burden; Vitamin E | 2018 |